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Abstract
Background: Extremely premature (birth weight < 1250 g) infants are at high risk for acquiring late-onset sepsis
and necrotizing enterocolitis, which are associated with significant mortality and morbidity. Own mother's milk
contains protective (immune and trophic) biofactors which provide antimicrobial, anti-inflammatory, antioxidant,
and immunomodulatory functions, enhance intestinal microbiota, and promote intestinal maturation. Many of these
biofactors are most highly concentrated in the milk expressed by mothers of extremely premature infants. However,
since extremely premature infants do not receive oral milk feeds until 32 weeks post-conceptional age, they lack
the potential benefit provided by milk (biofactor) exposure to oropharyngeal immunocompetent cells, and this
deficiency could contribute to late-onset sepsis and necrotizing enterocolitis. Therefore, oropharyngeal administration
of own mother's milk may improve the health outcomes of these infants.
Objectives: To compare the effects of oropharyngeal administration of mother’s milk to a placebo, for important
clinical outcomes, including (1A) reducing the incidence of late-onset sepsis (primary outcome) and (1B) necrotizing
enterocolitis and death (secondary outcomes). To identify the biomechanisms responsible for the beneficial effects of
oropharyngeal mother’s milk for extremely premature infants, including; (2A) enhancement of gastrointestinal (fecal)
microbiota (2B) improvement in antioxidant defense maturation or reduction of pro-oxidant status, and (2C)
maturation of immunostimulatory effects as measured by changes in urinary lactoferrin.
Methods/Design: A 5-year, multi-center, double-blind, randomized controlled trial designed to evaluate the
safety and efficacy of oropharyngeal mother’s milk to reduce the incidence of (1A) late-onset sepsis and (1B)
necrotizing enterocolitis and death in a large cohort of extremely premature infants (n = 622; total patients enrolled).
Enrolled infants are randomly assigned to one of 2 groups: Group A infants receive 0.2 mL of own mother's milk, via
oropharyngeal administration, every 2 hours for 48 hours, then every 3 hours until 32 weeks corrected-gestational age.
Group B infants receive a placebo (0.2 mL sterile water) following the same protocol. Milk, urine, oral mucosal swab,
and stool samples are collected at various time points, before, during and after the treatment periods. Health outcome
and safety data are collected throughout the infant’s stay.
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Background
Despite advances in neonatal medicine, extremely pre-
mature (birth weight < 1250 g) infants have substantial
mortality and morbidity, often resulting from infectious
morbidities including late-onset sepsis (L-OS) and nec-
rotizing enterocolitis (NEC) [1–8].
L-OS is highly prevalent (32–53 %) [6, 7], and costly
(approximately US $23,317 per episode) [8] for this
population. NEC accounts for an estimated US $6.5 mil-
lion in additional hospital costs yearly, in the United
States [3]. The risk for acquiring NEC is inversely related
to birth weight; therefore, extremely premature infants
have the highest incidence (10–12 %) of NEC, as well as
the highest NEC-associated mortality rates [4]. With in-
creased survival of premature infants, even a modest re-
duction in the incidence of L-OS and NEC could yield a
substantial cost savings, and improved health outcomes
for these infants. Minimizing these devastating infections
takes on a greater urgency – starting with the first days
of life.
L-OS is common in extremely premature infants be-
cause they are functionally immunodeficient, have an
immature intestinal mucosal barrier [9–11], and require
multiple invasive lines as part of their care. Pathogenic
(intestinal) bacteria are able to translocate across the
immature epithelial barrier and gain access to the blood-
stream, while invasive catheters allow pathogenic
bacteria a simple point of entry into the circulation.
While Gram-positive organisms (particularly coagulase-
negative Staphylococcus spp.) tend to be the predom-
inant pathogens causing L-OS in this population,
Gram-negative bacilli account for up to 30 % of epi-
sodes [12].
Compared to larger infants, extremely premature in-
fants are more frequently exposed to invasive procedures
and remain hospitalized in the pathogen-laden neonatal
intensive care unit (NICU) for a prolonged duration,
typically between 12–17 weeks. The long-term exposure
to pathogenic organisms in over-crowded NICU condi-
tions, overuse of antibiotics, delayed initiation of enteral
feeds, and presence of nasogastric tubes (NGTs) and
suction catheters are factors that decrease microbial di-
versity and promote abnormal microbiota [13], promot-
ing pathogen translocation with subsequent L-OS. The
immature gastrointestinal tract makes the tolerance to
enteral feeds problematic, and this necessitates the long-
term presence of an indwelling central venous catheter
for the provision of intravenous parenteral nutrition, fac-
tors which significantly increase the risk of L-OS.
The pathogenesis for L-OS is, therefore, multifactorial,
and studies suggest that lactoferrin supplementation
[14], early removal of invasive catheters and exposure to
human milk feedings can lower the risk [6, 7]. Lacto-
ferrin is a glycoprotein with potent anti-microbial,
anti-inflammatory, anti-oxidant and immunomodula-
tory functions [15–17]. It is contained in mother’s
milk (especially colostrum), and highly concentrated
in the milk expressed by women who deliver extremely
premature infants [16–18]. A recent multi-center ran-
domized controlled trial (RCT) [14] showed that preterm
infants who received exogenous (bovine) oral lactoferrin
supplementation had a significantly (50 %) reduced inci-
dence of L-OS (9/153; 5.9 %) compared to the placebo-
treated control group (29/168; 17.3 % (relative risk , 0.34;
95 % CI, 0.17–0.70; P = 0.002). Importantly, researchers
utilized a dosage of lactoferrin similar to concentrations
naturally found in human breast milk.
NEC, like L-OS, is associated with significant mortality
and long-term morbidities for extremely premature in-
fants. NEC is an inflammatory bowel necrosis which in-
volves mucosal injury, altered intestinal microbiota, an
unbalanced pro-inflammatory response, and abnormal
host defense [4]. NEC is common in extremely prema-
ture infants because they have an immature intestinal
epithelial barrier that is vulnerable to injury, a gastro-
intestinal microbiota which has a predominance of
potential pathogens, an unbalanced pro-inflammatory
response to pathogenic bacteria by immature entero-
cytes, decreased tight junctions between epithelial cells
(permitting the translocation of pathogens) and an im-
mature host defense system [4, 5, 13].
Pathogenic colonization of the preterm gut appears to
be a primary step in the pathogenesis of both L-OS and
NEC [5, 13, 19–21]. A pathogen-predominant micro-
biota promotes injury to the mucosal barrier and facili-
tates bacterial translocation from the gut into the
bloodstream [22]. Recent research suggests that specific
pathogens colonize the preterm gut before they invade
the bloodstream with subsequent L-OS, confirming the
importance of abnormal microbiota with subsequent
mucosal translocation as an important pathomechanism
[22, 23]. Therefore, optimizing the intestinal microbiome
in extremely premature infants could reduce the risk of
L-OS, and also NEC. Methods to enhance beneficial bac-
teria and improve microbial diversity may decrease the
risk for L-OS and NEC via multiple mechanisms. Expos-
ure to mother’s milk post-birth can reduce colonization
by pathogenic organisms and increase commensal bac-
teria, reducing bacterial translocation, modulating the
inflammatory response and decreasing intestinal injury
[24–27].
Mother’s milk feedings have been linked with im-
proved health outcomes for extremely preterm infants,
including a lower incidence and severity of L-OS, NEC
and enhanced neurodevelopmental outcomes [6, 28–33].
This protection is attributed to a multitude of pro-
tective (immune and trophic) biofactors, contained in
mother’s milk. Many of these biofactors are more
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highly concentrated in the milk expressed by women
who deliver extremely premature infants, particularly
in colostrum (early milk), and are also contained in
amniotic fluid. These biofactors include lactoferrin,
immunoglobulins, growth factors, hormones, enzymes,
antioxidants, nucleotides, polyunsaturated fatty acids,
erythropoietin, lysozyme, anti-inflammatory cytokines
and oligosaccharides [28–47]. Collectively, milk bio-
factors protect against L-OS and NEC, because of their
ability to provide antimicrobial, anti-inflammatory and im-
munomodulatory functions, inhibit pathogen adhesion to
the gastrointestinal mucosa, enhance gastrointestinal
microbiota, maintain the integrity of the intestinal barrier
and repair areas of injury, promote intestinal maturation
and motility, and provide antioxidant protection [24–47].
The ability for mother’s milk to promote an optimal
gastrointestinal microbiota, and stimulate healthy intes-
tinal homeostasis, is fundamental to its ability to protect
infants against L-OS and NEC [48].
Many biomechanisms likely contribute to mother’s
milk benefits, but based on compelling evidence and our
own preliminary data, we suggest that mother’s milk ef-
fects on microbiome, antioxidant defense, and immu-
nostimulatory lactoferrin are inter-related and together
contribute to a reduced incidence of infection and atten-
uated inflammatory responses. For example, recent
studies suggest that pro-oxidant status can directly in-
jury the intestinal epithelium and also disrupt the intes-
tinal microbiome [49]; increasing the risk for L-OS and
NEC. Lactoferrin, one of many biofactors contained in
mother’s milk, can protect against L-OS and NEC via
various mechanisms. First, lactoferrin has prebiotic and
bifidogenic actions, promoting the growth of healthy
commensals such as Bifidobacteria spp. and Lactobacilli
spp. [50]. Second, lactoferrin has maturational effects on
the intestine; promoting proliferation, growth and mat-
uration of enterocytes, and closing enteric gap junctions
[15]. Third, lactoferrin directly protects the intestinal
epithelium from injury due to oxidative stress [51] and
inflammation [52], and also prevents pathogen adhesion
to the epithelial barrier, preventing (pathogen) transloca-
tion into the bloodstream. Finally, lactoferrin modulates
cytokine production through direct contact with entero-
cytes and gut-associated lymphoid tissues [15, 52–55],
down-regulating pro-inflammatory mediators which can
injure the intestinal mucosa. Through these various
mechanism, lactoferrin promotes a healthy microbiome,
protects the intestine against injury, and prevents bacter-
ial translocation into the bloodstream, preventing both
L-OS and NEC. Understanding these important mecha-
nisms may not only provide information to better under-
stand the pathomechanisms for L-OS and NEC, but may
also lead to important new approaches for prevention
and treatment.
The milk expressed by women who deliver extremely
premature infants is more highly concentrated in many
protective biofactors – also present in amniotic fluid –
compared to milk expressed at term [16, 17, 56–65].
Colostrum (early milk) is especially protective [37].
While the link between mother’s milk feedings and a
decreased incidence and severity of infection is well-
established, these gestation-specific trends in compos-
ition may offer additional protection against infection,
for the extremely premature infant during the first weeks
of life [66]. However, clinical instability typically pre-
cludes enteral feeds for extremely premature infants in
the first days of life. Once started, enteral feeds are given
via a NGT which bypasses the infant’s oropharynx.
Therefore, the infant’s oropharynx is not exposed to pro-
tective (immune and trophic) milk biofactors until per
oral feeds are introduced several weeks post-birth [48]. If
mother’s milk is not available and formula is given, then
the infant’s oropharynx will never be exposed post-birth
to protective biofactors [48]. In a normal term pregnancy,
the fetus’s oropharynx is continually exposed to protect-
ive immune and trophic biofactors, which are present in
amniotic fluid, until 40 completed weeks of gestation.
We theorize that the lack of oropharyngeal exposure to
protective biofactors post-birth for extremely premature
infants, may be contributing substantially to many
prematurity-associated morbidities including L-OS and
NEC.
The particular influence of early (mother’s) milk ex-
posure to the extremely premature infant’s orophar-
ynx is unique and important. Experts postulate that
breastfed infants are protected against infection be-
cause of the immunostimulatory effects of protective
breast milk biofactors (including cytokines) on the in-
fant’s oropharyngeal-associated lymphoid tissue (OFALT)
[67, 68]. Thus, the exposure of milk biofactors to oropha-
ryngeal immunocompetent cells appears to be protective
and highly beneficial for the infant. While the term breast-
fed infant benefits from this protection, the extremely pre-
mature infant does not, and oral feeds are not introduced
until several weeks post-birth [48]. Oropharyngeal admin-
istration of mother’s milk [48, 66, 69, 70], may serve as a
natural alternative to provide a continuum of protective
effects post-utero for extremely premature infants [48].
With oropharyngeal administration, milk drops are
placed directly onto the infant’s oral mucosa [66, 69], so
that biofactors may provide immunostimulatory effects
[66–70]. Using this approach, we theorize that oropha-
ryngeal administration of own mother's milk is protect-
ive against L-OS and NEC [48] via several mechanisms:
1) interaction of milk cytokines with oropharyngeal im-
mune cells, 2) mucosal absorption of protective biofac-
tors, 3) barrier protection against pathogens, 4) local
and systemic effects of oligosaccharides which modulate
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intestinal microbiota and 5) beneficial effect of protect-
ive antioxidants. Milk cytokine interaction with OFALT
may provide immune stimulation. Mucosal absorption
of (milk) lactoferrin may result in higher concentrations
of urinary lactoferrin suggestive of systemic immune
protection against L-OS. A recent small (n = 48) RCT
[71], which was designed to determine the immunologic
effect of oropharyngeal colostrum administration,
showed higher concentrations of urinary lactoferrin for
milk-treated extremely premature infants at 1 week of
age, compared to placebo-treated controls (3.5 versus
0.9 μg/g creatinine P = 0.01). This finding is consistent
with our own pilot data [70], and suggests that lactofer-
rin may be absorbed via the mucosa with passage into
the circulation, and then excreted into urine following
oropharyngeal milk therapy [71]. During oropharyngeal
administration of mother’s milk, intestinal growth fac-
tors may also be absorbed mucosally or may travel to
the gut and accelerate intestinal maturation. Oligosac-
charides may be absorbed mucosally with systemic
effects, or may travel to the gut where they can exert
prebiotic effects enhancing Bifidobacteria spp. growth,
and also serve as decoy receptors to competitively
bind and inhibit pathogens, preventing translocation
and L-OS. Barrier protection (provided by lactoferrin
and secretory immunoglobulin A) prevents pathogen
adherence to epithelial cell surfaces in the gastrointes-
tinal tract, protecting against both L-OS and NEC.
Antioxidants protect immune cells from injury, pre-
vent oxidative stress-induced changes in microbiota
which promote pathogenic species and thereby reduce
inflammation and injury to the intestinal epithelium,
preventing translocation and protecting against L-OS
and NEC. Milk macrophages may also travel to the
gut, where they can survive for up to a week and
secrete intestinal growth factors and anti-inflammatory
cytokines [63].
Our previous studies [69, 70] established feasibility for
this technique and results were suggestive of immunosti-
mulatory effects [70]. Recent research from other inves-
tigators suggest additional benefits including protection
against ventilator-associated pneumonia, L-OS, NEC and
clinical sepsis, an earlier attainment of full enteral feeds,
enhanced maturation of oral feeding skills, improved
growth, enhanced immune function, and improved
breastfeeding outcomes [71–81]. An earlier attainment
of full enteral feeds has been reported in several studies
[70, 72, 76], and has important implications in terms of
L-OS risk. When full enteral feeds are reached sooner,
there is earlier removal of centrally placed venous
catheters and intravenous parenteral nutrition, signifi-
cantly reducing the infant’s risk for acquiring L-OS.
Findings from these published reports suggest that
oropharyngeal administration of mother’s milk may be
beneficial for extremely premature infants. However,
significant limitations, including small samples, retro-
spective analysis, and inconsistency in the technique,
limit generalizability.
Published reports are primarily from small retro-
spective cohort studies, feasibility trials, studies in
which oropharyngeal colostrum was included as part
of a standardized feeding protocol, and a recent small
(n = 48) RCT [71]. In published reports, investigators
used various terms to describe ‘oropharyngeal admin-
istration of milk’ including oral care, mouth care, oral
swabbing, oral colostrum and oral immune therapy.
However, the underlying premise was the same, placing
drops of mother’s milk (including early milk: colostrum)
into the infant’s mouth so that biofactors may stimulate
the infant’s oropharyngeal-associated lymphoid tissues,
providing protective immunomodulatory effects [48].
In published reports, there has been wide variation in
the technique, including significant variation in the dose
of milk administered (ranging from 0.1 mL to 1.0 mL),
in the frequency of treatments (every 2 to 6 hours and
also on an “as needed” basis), and in the duration of the
treatment protocol (from 2 to 7 days). Some investiga-
tors used syringes to draw up a precise volume of
mother’s milk, while others utilized a cotton swab
soaked with mother’s milk. Repeatedly dipping a swab
into a container of mother’s milk can contaminate the
milk with NICU pathogens and increase infection risk
for the infant. The use of a cotton swab increases the
risk that (cotton) fibers may be released during the ad-
ministration procedure and potentially aspirated. Im-
portantly, a cotton swab has been shown to absorb up to
97 % of the milk during 10 seconds of swabbing. Admin-
istering a precise volume with a sterile syringe, as op-
posed to soaking a swab in the milk, minimizes the
absorption of the milk into the swab. In this manner,
more milk remains on the mucosa for a consistent
“dose.”
We have tested many approaches but for this study,
we chose to deliver a precise (small volume) “dose”
(using a sterile syringe) followed by gently and brief
buccal swabbing with a small swab which has a polyur-
ethane foam head. The buccal swabbing serves to evenly
distribute the milk over the mucosa, but is done quickly
(≤5 seconds each side) and gently (with a non-cotton
swab) in order to avoid unnecessary friction and irrita-
tion to the fragile mucosal tissues.
In published reports, infants received colostrum, but
not mature milk, and the duration of treatment was
brief, ranging from 2 to 7 days. In our pilot studies, in-
fants also received only colostrum (not mature milk) for
the intervention, and the treatment period was only
48 hours in duration. However, for this current trial,
infants randomized to the treatment group receive
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colostrum and also mature milk, because we recognize
that (preterm) mature milk remains highly concentrated
in many protective biofactors. Since our premise is that
oropharyngeal administration of mother’s milk may serve
to mimic the protective effects of amniotic fluid biofactors
in the premature infant’s oropharynx [48], enrolled
subjects receive frequent “doses” of mother’s milk (or
placebo) until 32 weeks corrected gestational age (CGA);
when per oral feeds can be safely introduced.
In summary, the oropharyngeal administration of
mother’s milk appears to be beneficial for extremely pre-
mature infants; however, safety and efficacy have not
been established. While emerging evidence is promising,
small samples and wide variation in the technique limit
generalizability. An adequately-powered RCT is, there-
fore, needed to set the standard for this technique, and
to definitively establish the safety and efficacy of this
intervention for extremely premature infants.
Methods/Design
Study design
This study is a 5-year, prospective, double-blind, placebo-
controlled randomized clinical trial across 5 large neonatal
centers, designed to evaluate the safety and efficacy of
oropharyngeal administration of own mother's milk to
reduce the incidence of L-OS, and NEC and death, in
a large cohort of extremely premature infants (n =
622; total patients enrolled). A multi-center 5-year
trial is necessary in order to reach the target sample,
based on average numbers of extremely premature in-
fants admitted yearly to participating sites. Enrolled
infants are randomized to one of 2 groups using
computer-generated random numbers: Group A
(treatment) infants receive 0.2 mL of own mother’s
milk (OMM) via oropharyngeal administration every
2 hours for an initial treatment period of 48 continuous
hours, followed by an extended treatment period of
0.2 mL of OMM via oropharyngeal administration every
3 hours until 32 weeks CGA. Group B infants (control) re-
ceive a placebo (sterile water, and blinded as described
below) using the same dose and following the same
protocol. Samples of mother’s milk and infant’s urine are
collected at baseline and within 6 hours after the comple-
tion of the Initial Treatment Period and the Extended
Treatment Period. A sample of infant’s urine is collected
at 7 days of life. Milk, oral mucosal swab, and stool sam-
ples are collected at the time of first stool, 2 weeks of life
and at 32 weeks CGA. For infants diagnosed with L-OS or
NEC, a stool sample is collected at the time of diagnosis.
Health outcome and safety data are closely monitored and
collected throughout the infant’s stay until discharge or
death. See Fig. 1 for the timeline of the study.
Study approval
The study was approved by the Institutional Review
Board (IRB) at the NorthShore University HealthSystem
(primary site) and by the IRBs at the New Hanover
Regional Medical Center and the St. Joseph’s Regional
Medical Center. Subject enrollment is in progress at
these three study sites. Recruitment at the Advocate
Children’s Hospital and also the Morristown Medical
Center study site will not begin until IRB approval has
been obtained. All investigators, treating physicians and
nurses, project director, data analyst, and lab technicians are
blind to group assignment, except the (site) research nurse
who assigns subjects into groups and prepares syringes.
Study site and population
Infants are being recruited from 5 NICUs in hospitals
within the United States: (1) NorthShore University
HealthSystem in Evanston, IL, (2) Betty H. Cameron
Women & Children's Hospital (New Hanover Regional
Medical Center) in Wilmington, NC, (3) St. Joseph’s
Children’s Hospital in Paterson, NJ; (4) Advocate
Children’s Hospital in Park Ridge, IL (recruitment will
not begin at this site until IRB approval is obtained) and
(5) Morristown Medical Center in Morristown, NJ
(recruitment will not begin at this site until IRB approval
is obtained). We anticipate a study population com-
prised of the following demographics: 31 % African
American, 35 % Non-hispanic Caucasian, and 27 %
Hispanic, 3 % Asian and 4 % Other.
Fig. 1 Timeline of the study. After informed consent is obtained, the infant is enrolled, randomized, and begins receiving treatments. The
treatments are given until the infant reaches 32 weeks CGA. Health outcome data is collected throughout the infant’s hospitalization until NICU
discharge. CGA, corrected gestational age; NICU, neonatal intensive care unit
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Inclusion/exclusion criteria
Extremely premature infants are eligible for the study if
they meet the following inclusion criteria: birth weight
< 1250 g; mother plans to pump and provide milk for at
least 2 months; absence of severe congenital anomalies;
NICU admission ≤ 24 hours of life; ability to begin proto-
col within 96 hours of life. The exclusion criteria are
as follows: birth asphyxia (cord pH/arterial pH < 7.0);
presence of a tracheoesophageal fistula, maternal + HIV
status, maternal drug or substance use that precludes
infant from receiving mother’s milk, triplets or higher
order multiple births.
Participant recruitment, enrollment and informed consent
The collaborating sites have a relatively high census
of extremely premature infants yearly and very high
lactation initiation rates (80–90 %) which facilitates
subject recruitment. Mothers on bed rest protocols in
the high risk antenatal unit, who meet inclusion criteria
(estimated fetal weight < 1250 g per prenatal ultrasound)
are approached and invited to participate. In our pilot
studies, this recruitment strategy was highly successful
and the majority of women approached agreed to partici-
pate. Mothers who deliver without significant time in the
antenatal unit are approached within 96 hours after
delivery.
The principal investigator (PI) and/or research nurse
explain the study in detail, answer questions, and leave
the consent form so that the mother can read it and dis-
cuss the study with her family prior to enrolling. A sec-
ond meeting is scheduled later that same day, when
convenient for the mother, and the PI and/or research
nurse return and answer any additional questions.
Informed consent is obtained at this time (second
meeting) if the mother decides to participate. This
precaution is taken because these women are consid-
ered psychologically vulnerable, in terms of research.
Mothers are informed that their care (or their baby’s
care) will not be affected if they decide not to partici-
pate in this study. In addition, mothers are informed
that they have a right to withdraw their infant (or
themselves) from the study at any time and for any
reason without compromise to their care, or their in-
fant’s care.
If the woman is approached antenatally, before secur-
ing informed consent, the PI and/or research nurse ex-
plain to her that if she remains pregnant and the
estimated fetal weight (EFW) is over 1250 g per prenatal
ultrasound, then the infant, once born, will no longer
qualify for the study. This is deemed a screen failure
since the infant will no longer meet inclusion criteria.
All women are assured that their infant’s care, and their
breastfeeding support post-birth, will not be affected by
their decision to participate in the study, or if they
become ineligible. Since 27 % of enrolled mothers are
expected to be Hispanic, Spanish-IRB-approved transla-
tions of study documents are available at all sites.
Randomization
A 1:1 blocked randomization scheme was utilized to
yield “comparable” subjects in each of the 2 groups,
stratified by birthweight (<750 g, 751–999 g, 1000–
1250 g) within each site, to avoid imbalance in the distri-
bution of the 2 groups at each site. We produced a sep-
arate block randomization list within each site for each
subgroup (a total of three strata). The randomization is
based on permutated blocks with random sizes varying
from 2 to 4 (to avoid guessing) to make sure that each
site will have an equal number of participants in each
group. The randomization list was generated prior to
study initiation using a random seed number via SAS
PROC PLAN (SAS Inc., Cary, NC, USA) to generate the
stratified randomization design. The statistician prepared
sealed, numbered opaque envelopes for each site, with
randomization assignment inside. The envelopes were
given to the site’s research coordinator who assures that
they are used in numerical order. After informed con-
sent is obtained, the research coordinator opens an en-
velope, removes the group assignment form, writes the
infant’s study ID # and date on the form, makes a copy
of the form and sends it to the statistician, keeping the
original in the infant’s study file. Group A (treatment)
infants receive OMM, while Group B (control) infants
receive a placebo (sterile water). In the case of a multiple
birth, twins are stratified and randomized into either the
intervention or the control group, and will be analyzed
independently between the two experimental groups.
Triplets or higher order multiple births are not be eli-
gible for the study.
Retention The major issue with retention is the need
for mothers to provide milk until their infant reaches
32 weeks CGA. While most will be motivated to do so
(based on our experience) we have conservatively esti-
mated a 20 % dropout rate to account for mothers who
discontinue pumping (based on previous experience).
Only a very small volume (< ½ teaspoon) of milk is
needed daily for the intervention and, as our pilot data
shows that all mothers can readily express this amount,
this should not be problematic.
Study procedures
Collection of milk Research personnel within each
site have been trained, using a standardized protocol
(Protocol version 4; Dated 1/5/2015), to assure coher-
ence of data collection. Mother’s milk samples are
collected during the routine expression of milk, using
a hospital-grade electric breast pump, and are stored
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in the NICU breastmilk refrigerator. When at least
2.5 mL (½ teaspoon) of mother’s milk is available, the
research nurse prepares the syringes for the first
24 hours of the Initial Treatment Period. For infants
in the placebo group, the milk is immediately frozen,
in a separate NICU breastmilk freezer to maintain
blinding, for later use when enteral feedings are
started. Using sterile gloves, 24 sterile oral syringes
are each filled with 0.1 mL of OMM or sterile water
(based on group assignment), capped, and covered
with a white tape as a blinding procedure. Each syr-
inge is labeled with the patient’s name, medical rec-
ord number, and the date and time of preparation.
Syringes are prepared in the same sterile manner, by
the research nurse, every 24 hours. For the Extended
Treatment Period, a total of 16 syringes are prepared
daily, for treatments to be given every 3 hours.
It is standard practice to encourage mothers of ex-
tremely premature infants to pump frequently (typically
every 3 hours) in order to establish and maintain an
abundant milk supply. Therefore, it is common for
NICU nurses to see several containers, with varying
amounts of mother’s milk, in the NICU refrigerator, on
a daily basis. The milk is either used for enteral feeds or
frozen for storage. Since only miniscule volumes of milk
are needed daily for this intervention (2.4 mL and
1.6 mL per day, for Initial and Extended Treatment
Periods, respectively) it has been our experience that
NICU nurses do not notice that a small volume of milk
has been removed from the refrigerator, and thus they
remain blind to group assignment.
Oropharyngeal administration procedure Using a
standardized protocol, the nurse provides the dosing as
follows: two syringes are warmed to room temperature.
The first syringe’s cap is removed and the tip of the syr-
inge is gently placed into the infant’s mouth, alongside
the right buccal mucosal tissue. The syringe tip is di-
rected posteriorly towards the oropharynx, and the total
volume (0.1 mL) is slowly administered, over at least
1 minute. The second syringe is placed in the infant’s
mouth in the same manner, but alongside the left buccal
mucosal tissue. The entire volume (0.1 mL) is adminis-
tered slowly, over at least 1 minute. A petite swab is
used to carefully swab the right buccal mucosal tissue,
followed by the left buccal mucosal tissue (≤5 seconds
each side). A total volume of 0.2 mL is administered per
treatment, with buccal swabbing taking place over
10 seconds. Vital signs are carefully monitored through-
out the procedure. The procedure is repeated every
2 hours for 48 consecutive hours during the Initial
Treatment Period, which begins within the infant’s first
96 hours of life. The Extended Treatment Period begins
immediately after the Initial Treatment Period has been
completed and ends when the infant reaches 32 weeks
CGA as depicted in Fig. 2. Dosing is provided every
3 hours during the Extended Treatment Period. Partici-
pation in this study does not interfere with the initiation
or progression of enteral feedings, which is left to the
discretion of the attending physician. Urine, oral muco-
sal swabs, and stool specimens are collected from en-
rolled infants, and milk samples from their mothers, at
specific time points, as depicted in Fig. 2.
Objectives Our specific Aim 1 is to compare the effects
of oropharyngeal administration of mother’s milk to a
placebo, for important clinical outcomes, including (1A)
reducing the incidence of L-OS (primary outcome) and
(1B) NEC and death. Our specific Aim 2 is to identify
the biomechanisms responsible for the beneficial effects
of oropharyngeal administration of mother’s own milk
for extremely premature infants including (2A) enhance-
ment of gastrointestinal (fecal) microbiota (2B) improve-
ment in antioxidant defense maturation or reduction of
pro-oxidant status, and (2C) maturation of immunosti-
mulatory effects as measured by changes in urinary
lactoferrin.
Sample size/Power analysis We hypothesize that ex-
tremely premature infants who receive oropharyngeal
administration of mother’s milk will have a significantly
lower incidence of L-OS (primary endpoint). Based on
recent (2012) data from the Vermont-Oxford Network
that included > 20,000 ELBW infants, the incidence of
L-OS in this population was 19.4 %. Based on data
from Manzoni et al. [14], that showed a reduction of
L-OS from 17 % to 6 % with exogenous bovine
lactoferrin in preterm infants, we conservatively esti-
mate a reduction in L-OS from 20 % to a total of
10 % in milk-treated infants. Since Manzoni et al.
[14] used a lactoferrin dose similar to that in mother’s
milk, and based on studies that mother’s milk reduces
L-OS [6–8] this effect size of reduction (from 20 %
to 10 %) should be realistic and obtainable given the
patient population. Since many variables may alter the
risk for L-OS in extremely premature infants multi-
variable logistic regression (for dichotomous L-OS
outcome) will be performed adjusting for covariates
such as sex, gestational age and birth weight. Power
calculations were determined using PASS 14.0 soft-
ware (NCSS, LLC, Kaysville, UT, USA). We estimate
that up to a total of 10 covariates will account for a
combined 20 % (R2 = 0.2) of variance in the regression
model. Based on a 2-tailed alpha of 0.05 and 80 %
power, a sample size of 498 (249 in each group) will
be needed to reach a statistical power of 80 % to de-
tect a difference of 10 % versus 20 % (effect size odds
ratio (OR) = 0.44) in L-OS outcome between milk and
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placebo groups. Therefore, the study is adequately
powered for the primary endpoint L-OS. The study
sample is being accrued from 5 sites and, based on a
lactation initiation rate of > 70 % for all sites (conser-
vative, based on actual rates of 80–90 %), and an es-
timated refusal rate of 30 % (a conservative estimate
based on our previous experience in recruiting sub-
jects for this intervention), we will screen a total of
1270 patients to enroll 622, with an estimated drop-
out rate of 20 %, that will allow us a complete ana-
lysis for 498 subjects.
Outcome measures for specific Aim 1 Primary end-
points: L-OS is defined as the new onset of at least 2 clin-
ical symptoms with a positive blood culture (noted after
Day of life 3) and identification of an organism known
to be a cause of sepsis rather than a contaminant. If the
blood culture shows a potential contaminant (such as
Staphylococcus epidermidis) a second blood culture is
obtained to confirm the presence of bacteremia.
Secondary endpoints: NEC and death. NEC is defined
according to modified Bell’s criteria stage > 2 with clin-
ical signs and radiological evidence including any of the
following: pneumatosis intestinalis, portal venous gas
with or without pneumoperitoneum.
Covariates: sex, gestational age and birth weight will
be included as covariates.
Safety endpoints: health outcome and safety data are
closely monitored and collected throughout the infant’s
stay until discharge or death. Infant safety is being
assessed through the monitoring for adverse events by
the Data Safety and Monitoring Board (DSMB), com-
prised of independent reviewers. The DSMB meets every
6 months during the first year of active enrollment, and
thereafter at ¼, ½ and ¾ enrollment to ensure rapid
identification of adverse events. Adverse events are de-
fined to include aspiration, significant bradycardia fol-
lowing (oropharyngeal milk) administration leading to
the need for resuscitation, and post-natal acquisition of
cytomegalovirus (CMV) thought to be associated with
fresh milk. Studies have identified the potential risk of
milk-acquired CMV infection, but based on the small
volumes and controversial risk (even with frozen milk),
we promote fresh milk as our standard in this study, as
we did with our pilot studies, and follow clinically for
symptoms of acquired CMV and will intervene quickly
if a case should arise. To maintain safety of enrolled
infants, vital signs are carefully monitored during the
oropharyngeal administration of the study substance
(milk or sterile water). The nurses are instructed to
immediately stop the procedure and to notify the site
PI if any of the following signs of aspiration should
occur: an increase in fraction of inspiratory oxygen > 0.1
to maintain a SpO2 > 85 %, bradycardia (heart rate
(HR) < 100/minute), tachycardia (HR > 200/minute),
tachypnea (respiratory rate (RR) > 80/minute), or apnea.
Treatments are withheld during surgical and invasive
procedures or based on clinical evidence of acidosis,
NEC, multisystem organ failure, or other instances of
clinical deterioration, but this decision is left to the dis-
cretion of the attending physician after discussion with
the site PI (another neonatologist).
Built into this study, are interim analyses by the DSMB
that will evaluate any significant adverse events that may
require altering study protocol over the course of the
study, and to analyze whether results with one arm are
not significantly beneficial compared to the other. Ad-
verse events could occur in the intervention and placebo
groups (for bradycardia and aspiration). Ad-hoc DSMB
meetings can be requested at any time if the PI or site
investigators identify a potential safety issue. The PI is
responsible for accurate documentation, investigation
and follow-up of all study-related unanticipated serious
events in a timely manner. To ensure that study-related
unanticipated serious events are identified and managed
expeditiously, the following reporting mechanism will be
Fig. 2 Study flow chart. Enrolled infants are randomized to receive either own mother’s milk or a placebo during the initial treatment period and
the extended treatment period. Biological specimens (milk, urine, stool and swab of oral mucosa) are collected at specific time-points as depicted.
CGA, corrected gestational age; L-OS, late-onset sepsis; NEC, necrotizing enterocolitis
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implemented: the PI (Dr. Rodriguez) will be notified im-
mediately by the site investigator (collaborating neonat-
ologist) of any study-related unanticipated and adverse
events or serious safety issues. The PI will immediately
request an ad-hoc DSMB meeting to review safety data.
The DSMB will review the study-related unanticipated
and adverse events and will make a determination as to
whether the study should be continued, modified or ter-
minated. The DSMB Chair will forward the report to the
PI, who will submit the report to the NorthShore IRB
and to site investigators (collaborating neonatologists) at
each study site, who must, in turn, submit the report to
their local IRBs. The report will include the DSMB’s
recommendations to the IRB as to whether the study
should be continued, modified or terminated. Any action
taken by the IRB will be reported by the PI to the
DSMB, and to site investigators and their IRBs.
Statistical analysis Statistical analysis will be performed
using an intention-to-treat (ITT) approach. Baseline in-
fant and mother demographics and clinical characteris-
tics will be summarized between milk and placebo
groups using a chi-square or Fisher exact test for cat-
egorical variables (i.e. infant gender, race/ethnicity, so-
cioeconomic status, maternal diagnosis of pre-eclampsia,
premature and/or prolonged rupture of membranes,
delivery mode, and steroid administration) and an inde-
pendent t test or a Wilcoxon two-sample test for con-
tinuous variables (i.e. the time of initial exposure to
mother’s own milk, duration [number of days] of central
line placement and mechanical ventilation, gestational
age, birth weight, post-natal steroids, antibiotic dur-
ation), depending on satisfying the normality assumption
or not, respectively. A multivariable logistic regression
with L-OS or NEC or death as the dependent variable,
and group (milk versus placebo) as the primary inde-
pendent variable will be constructed to assess the
strength of association between oropharyngeal milk
treatment and risk of L-OS or NEC or death, adjusting
for pre-specified covariates including sex, gestational age
and birth weight. Odds ratios and corresponding 95 %
confidence intervals will be reported. Because the
amount of mother’s milk that enrolled infants receive as
a “feeding” will affect our study endpoints, we will
closely monitor and record the total amount of mother’s
milk received (percent of total feeding volume) for each
study subject. We do not anticipate the amount of milk
the infant receives as an enteral feed will be affected by
group assignment. However, if we do observe a signifi-
cant difference between the intervention and placebo
groups, we will control for this variable in the regression
models. While the main hypotheses will be tested using
ITT analysis, we will also conduct per protocol ana-
lysis only for patients who complete the treatment.
Completed treatment is defined as (the infant) having
received 70 % of planned doses. However, this will be
considered supplemental and exploratory, and the results
will not be used as main conclusions of the study.
Analysis of safety endpoints Safety endpoints will be
analyzed using summary statistics (frequency, count,
percent). We will compare each safety endpoint between
milk and placebo groups using chi-square and Fisher
exact tests. We will also analyze the safety endpoint
count data by conducting Poisson regressions using
group (milk versus placebo) as the independent variable,
controlling for covariates described above if applicable.
Outcome measures for specific Aim 2 This is an
exploratory aim of the trial and, therefore, should not be
considered as the primary endpoint of the study. We
hypothesize that oropharyngeal administration of OMM
will modulate microbiome, antioxidant status and urin-
ary lactoferrin concentrations for recipient infants.
These measures are described below.
Microbiome We hypothesize that mother’s milk will
modulate fecal microbiota of extremely premature in-
fants leading to increased microbial diversity with a
Lactobacillus/Bifidobacterium predominance and de-
creased Proteobacteria. Samples of milk, oral mucosa
swabs, and stool are collected at the time of first stool,
2 weeks of age and at 32 weeks CGA for enrolled sub-
jects and frozen immediately at −80 °C. For subjects
who develop L-OS or NEC an additional stool sample is
obtained at the time of diagnosis, and results correlated
with the 32 -week samples. The composition and struc-
ture of the microbiome from milk, oral mucosa, and
stool will be tracked using high-throughput 16S rRNA-
based gene analysis as per previously published proto-
cols [20, 82].
Antioxidant status We hypothesize that the oxidative
stress associated with prematurity will be diminished
with oropharyngeal administration of OMM, as mea-
sured by changes in levels of validated urinary bio-
markers of oxidative stress, and this will correlate with
the development of L-OS (late onset sepsis) and NEC
(necrotizing enterocolitis).
Extremely premature infants are predisposed to oxida-
tive stress-derived diseases because of (1) the need for
oxygen supplementation in the first weeks of life with an
overproduction of highly reactive oxygen-derived free
radicals (FR) capable of causing damage to DNA, pro-
teins and lipids; (2) immaturity of the antioxidant en-
zymatic and non-enzymatic defense system [83–89]. The
deleterious action of free radicals upon proteins, lipids,
and DNA can be assessed by determining highly specific
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biomarkers using ultra high performance liquid chroma-
tography coupled to tandem mass spectrometry (UPLC-
MS/MS) methods that have been validated using Food
and Drug Administration (FDA) stringent requirements.
Our hypothesis is based on previous observations by
our research team (Dr. M. Vento) showing that human
milk-fed preterm infants have better antioxidant capacity
compared to formula-fed cohorts [87]. Dr. Vento has
established normative ranges for the measurement by
UPLC-MS/MS of urinary biomarkers in extremely pre-
mature infants reflecting oxidative damage to proteins
[87, 88]. His research has validated the whole spectrum
of metabolites derived from phenylalanine (Phe) oxida-
tion by non-physiologic pathways (orto, meta, nitro,
3Chlor-tyrosines) and oxidative damage to guanidine
bases of DNA (8-oxo-dihydroxi-guanosine), and non-cy-
clo-oxygenase (COX) derived oxidative byproducts of
arachidonic and docosahexanoic acid, essential compo-
nents of cell membranes, in extremely premature infants
such as F2-isoprostanes, specific Prostaglandins (PGs),
Isofurans (IsoFs), Neuroprostanes (NeuPs) and Neuro-
furans (NeuFs).
The approach used to test this hypothesis will be the
PGs and isoprostanes (IsoPs) in urine samples of the
first 50 (25 milk, 25 placebo) enrolled infants, collected
at 4 time points as depicted in Fig. 2. UPLC-MS/MS
analysis is carried out on an Acquity-Xevo TQ system
(Waters, Milford, MA, USA) using negative electrospray
ionization. MS/MS detection is carried out by multiple
reaction monitoring (MRM) employing specific acquisi-
tion parameters. In milk-treated infants, we anticipate
lower elimination of oxidized tyrosines, oxidized bases
of DNA and IsoPs and PGs compared to baseline. We
expect urinary metabolites of the placebo-treated infants
to be within the established ranges for the different
metabolites.
Lactoferrin We hypothesize that oropharyngeal admin-
istration of OMM will be associated with higher concen-
trations of urinary lactoferrin in treated infants. Our
hypothesis is based on our pilot data [70], which showed
higher concentrations of urinary lactoferrin in infants
who received oropharyngeal administration of mother’s
colostrum, compared to placebo-treated controls. No
significant between-group differences were found; how-
ever, the sample size was small (n = 16). A large effect
size (1.30) was noted for urinary lactoferrin, which sug-
gests that results may have reached statistical signifi-
cance if a larger sample had been used. This finding is
consistent with research that has shown higher concen-
trations of urinary lactoferrin in mother’s milk-fed in-
fants compared to formula-fed cohorts [90, 91]. Further
studies have shown that the urinary lactoferrin is of ma-
ternal origin [92–94], although the precise mechanism
of entry into the urine is unknown. The approach used
to test this hypothesis will be the measurement of lacto-
ferrin in urine samples at 3 time points (see Fig. 2),
using a commercial ELISA assay. Lactoferrin concentra-
tions will also be measured in milk samples from
mothers, at the same three time points, to clarify
whether the infant’s levels are due to the milk or from
neonatal immune responses resulting from other factors.
A mixed-effects regression model will be applied to as-
sess whether the average at each time point or change
over time is different between the two groups. The ana-
lysis will be done first for infant and mother separately,
then an index variable will be created to define mother
versus infant, and the difference between mothers and
infants will be assessed. Appropriate variance-covariance
structure will be determined by Akaike Information
Criterion (AIC). Normality assumption will be evaluated
using Shapiro-Wilk’s test or visualization of data distri-
bution. Appropriate data transformation (i.e. log, square
root) will be applied to correct the skewness.
Data management and quality control The goals of
data management are: (a) to ensure that data collected
across sites are properly and accurately entered and doc-
umented; (b) to ensure that data will be stored in an
electronic format that will allow the primary investiga-
tors of the project to retrieve data easily and to export
data to statistical packages; and (c) to ensure the confi-
dentiality of subjects. Prior to data collection and entry,
a standard codebook was created which contains the
variable names, descriptions, and value codes of each
variable/item collected within each site. Following devel-
opment of the codebook, a web-based SQL (Structural
Query Language) data capture and archiving system was
created using REDCap to standardize data collection
across the five study sites. The web-based REDCap ap-
plication, developed by Vanderbilt University, offers in-
tuitive design and tailored clinical research workflows
that enable research team members across collaborating
study sites to share, capture and manage data. REDCap
provides secure user-friendly web-based case report
forms, real-time data entry validation (e.g. for data types
and range checks) and audit trails. Users from different
sites can be assigned different levels of access which can
be form or rights based. All data are stored in the
password-protected network server at NorthShore with
back-up scheduled at every midnight. The original raw
data within each site is stored in a locked cabinet
accessed only by key project personnel. For quality con-
trol, we have developed and implemented standard pro-
tocols for data collection and enrollment monitoring
across study sites. We have also implemented communi-
cation systems and documentation of study-related
plans, decisions, progress, and analysis management for
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efficiently throughout all phases of the research. All re-
search personnel within each site have been trained
using a standard protocol. The training covers areas
such as recruiting, enrollment, randomization, and web-
based data collection.
The PI, Project Director and Data Manager conduct
interim sites visits to collaborating study sites, to audit
data for quality assurance, ensure protocol compliance
and to address any issues. All IRB and Health Insurance
Portability and Accountability (HIPAA) regulations are
strictly enforced. The entire research team (including
site PIs and research nurses) meet via conference call
monthly, and as needed, to discuss enrollment, adher-
ence to protocol, and to promptly address any issues.
Missing data For missing data or gross outliers, we will
use several strategies to handle missing, out-of-range,
and potentially erroneous data (depending on the level
of measurement of the variables) including considering
patterns driven by demographics and behavioral factors
to guide replacement decisions and replacing missing
values with those generated through multiple imputation
using SAS PROC MI (SAS Inc., Cary, NC, USA) proced-
ure if missing data are MCAR (data are missing com-
pletely at random) or MAR (data are missing at random).
If missing data are NMAR (not missing at random), we
will use the “pattern mixture” approach to compute a
“weighted average” of the parameters that are associated
with the missing data to estimate what the data would
have been.
Discussion
This multi-center, double-blind RCT was designed to
evaluate the safety and efficacy of oropharyngeal admin-
istration of OMM to reduce the incidence of L-OS and
NEC in a large cohort of extremely premature infants.
For treated infants, we anticipate beneficial gastrointes-
tinal effects (e.g. trophic effects on the intestine and a
predominance of beneficial microflora), immunostimula-
tory effects (higher concentrations of urinary lactoferrin),
enhanced antioxidant status (measured by changes in
levels of urinary biomarkers of oxidative stress), and a
decreased incidence of L-OS and NEC.
To date, 77 subjects have been enrolled. There have
been 11 screen failures because consent was obtained
antenatally (per protocol), but once the mother gave
birth the infant’s weight was over 1250 g and he/she was
no longer eligible for the study. The remaining 66 sub-
jects have completed treatment. A total of 13,433 treat-
ments have been administered to enrolled subjects,
corresponding to a total of 26,866 syringes having been
prepared. Importantly, subjects have received > 90 % of
planned treatments; demonstrating strict adherence to
the rigorous research protocol. For each infant, once
enrolled, we carefully calculate the number of “planned
doses” to be given. This calculation is based on the in-
fant’s gestational age at birth and the date the infant will
reach 32 weeks CGA. On a daily basis, we track the
number of treatments that are given. Each dose that is
administered is documented in the infant’s intake flow-
sheet, in the medication administration record, and also
in a study-specific form. Bedside nurses are blind to
group assignment and document the “dose” adminis-
tered as “study substance.” At the completion of the ex-
tended treatment period, the percent of “planned doses”
that were actually given, is calculated and recorded.
Completed treatment is defined as (the infant) having re-
ceived 70 % of planned doses.
All doses have been well-tolerated by enrolled in-
fants and no adverse effects have been reported. In-
fant safety is carefully assessed as described in the
previous section.
We are recruiting infants from five large tertiary neo-
natal centers. We anticipate a racially, ethnically and eco-
nomically diverse cohort, with broad representation of
medically underserved women and minorities, and suffi-
cient numbers from which to recruit and test our aims.
If aims are achieved, this study will set the standard
for a consistent technique so that risks are minimized
and patient safety is ensured. The evidence derived from
this current study, whether positive or negative, will
quickly impact neonatal clinical practice nationwide.
Dissemination policy Sharing of data generated by this
project will be an essential part of this trial and will be
carried out in several different ways. We would wish to
make our results available to both neonatal clinicians
(physicians, nurses, dieticians, and lactation consultants,
among others) and the community of scientists interest-
ing in improving outcomes for extremely premature in-
fants. Our plan includes the presentation of results at
national scientific meetings. We will also submit several
manuscripts for publication in peer-reviewed medical
and nursing journals, based on the data generated from
this project.
Trial status
This is a current, ongoing trial which is actively recruit-
ing subjects. We expect to finish patient recruitment in
September 2018 and will present final results over the
course of 2019.
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